

Please amend the claims (attached as annexes to the International Preliminary Examination Report filed herewith) as follows:

Please cancel claims 1-29 without prejudice to or disclaimer of the subject matter contained therein. Applicants reserve the right to prosecute the subject matter of these claims in one or more continuing applications.

Please add the following new claims:

30. (New) A conjugate comprising a first lectin coupled to a peptide or protein, wherein said first lectin is non-endogenous to humans, and wherein said peptide or protein is substantially free of Clostridial neurotoxin enzyme activity.

31. (New) A conjugate according to Claim 30 wherein the peptide or protein is a second lectin.

32. (New) A conjugate according to Claim 30 wherein the first lectin binds to a galactosyl residue.

33. (New) A conjugate according to Claim 30 wherein the first lectin binds to a glucosyl residue.

34. (New) A conjugate according to Claim 31 wherein the first and second lectins are different.

35. (New) A conjugate according to Claim 34 wherein the first lectin binds to a galactosyl residue and the second lectin binds to a glucosyl residue.

36. (New) A conjugate according to Claim 30, wherein the peptide or protein is an endopeptidase, or a Clostridial neurotoxin substantially free of enzyme activity.

37. (New) A conjugate according to Claim 30, wherein the first lectin is a lectin derivative, said derivative having been modified to remove a carbohydrate group while maintaining the ability of the derivative to bind C-fibres.

38. (New) A nucleic acid sequence encoding the conjugate of Claim 30.

39. (New) A method of treating a disease or condition resulting from an inhibition or stimulation of C-fibre neuron activity, by modulating C-fibre activity, comprising administering an effective amount of a lectin, or a conjugate according to Claim 30, or a nucleic acid sequence according to Claim 38, to a patient.

40. (New) A method according to Claim 39 for inhibiting C-fibre activity.

41. (New) A method according to Claim 39 for stimulating C-fibre activity.

42. (New) A method according to Claim 39 wherein said disease or condition is selected from the group consisting of pain, psoriasis, inflammation and mucus hypersecretion.

43. (New) A method of preparing a conjugate according to Claim 30, comprising coupling together, optionally via a linker, the first lectin and the peptide or protein.

44. (New) A method of preparing a conjugate according to Claim 30, comprising expressing in a host cell a nucleic acid sequence according to Claim 38, optionally including a linker nucleic acid sequence located within said nucleic acid sequence provides a linker molecule between the first lectin and the peptide or protein of the conjugate.

45. (New) A composition comprising a lectin and a peptide or protein, wherein the peptide or protein is an endopeptidase or a Clostridial neurotoxin free of enzyme activity.

46. (New) A composition according to Claim 45, wherein the peptide or protein is an LH_N fragment of a Clostridial neurotoxin.

47. (New) A method of treating a disease or condition resulting from an inhibition or stimulation of C-fibre neuron activity, by modulating C-fibre activity, comprising administering a composition according to Claim 45 to a patient.